Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review

Review (16 publications) found that low dose capecitabine may be linked to decrease in incidence of squamous cell carcinomas in high-risk patients, including solid organ transplant recipients, however, adverse effects limited the duration of chemoprevention in several patients.

Source:

JAMA Dermatology